Month: September 2025

Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD

New U.S. patent provides IP coverage for the formulation to 2042Further expands Starton’s intellectual property portfolio surrounding its lead product...

Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD

New U.S. patent provides IP coverage for the formulation to 2042Further expands Starton’s intellectual property portfolio surrounding its lead product...

Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)

error: Content is protected !!